Skip to content

Scientific Technology News

About STN
Contact Us

Top-10
Instrument Industry Deals
Product Launches

Merck KGaA, Darmstadt, Germany Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody

June 4, 2017October 21, 2019 by /

Share This.....

Share on linkedin

Share on twitter

Share on facebook

Share on google

Related News:

FDA approves Roche’s Vabysmo, the first bispecific…
FDA approves Roche’s Vabysmo, the first bispecific…
CHMP recommends EU conditional approval of Roche’s…
New pivotal data demonstrate clinical benefit of…
New pivotal data demonstrate clinical benefit of…
European Commission approves Roche’s first-in-class…

Share this:

Click to share on Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)

Category: Clinical Research/Diagn., Lab Top-10, M&A, Partnerships Tag: Merck KGaA

Post navigation

Previous PostBristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

Next PostShimadzu Corporation and Phytronix Technologies sign an agreement to offer the first Triple Ion Source (LDTD-MS/MS, ESI-MS/MS and APCI-MS/MS).

Get market data and industry analysis here. Request a complimentary copy.

Related News

FDA approves Roche’s Vabysmo, the first bispecific… January 31, 2022
FDA approves Roche’s Vabysmo, the first bispecific… January 31, 2022
CHMP recommends EU conditional approval of Roche’s… April 22, 2022
New pivotal data demonstrate clinical benefit of… May 27, 2022
New pivotal data demonstrate clinical benefit of… May 27, 2022
European Commission approves Roche’s first-in-class… June 8, 2022
CHMP recommends EU approval of Roche’s Vabysmo, the… July 22, 2022
European Commission approves Roche’s Vabysmo, the… September 19, 2022
FDA grants priority review to Roche’s bispecific… January 6, 2023
FDA approves Roche’s Lunsumio, a first-in-class… December 23, 2022

© 2024 Scientific Technology News